Aceto Consolidates Acquisition of Six Manufacturers over 18-Months, Strengthening Its Unique Hybrid Model that Provides Major Supply Chain Benefits to Customers
Manufacturing acquisitions complement existing strengths in global procurement and distribution, providing supply chain flexibility and dependabilty to biopharmaceutical and other specialty customers
GMP manufacturing footprint extended to North America, Europe and India
Provides enhanced capabilities throughout the R&D and drug development process
Increase psroduct offerings in GMP manufacturing, packaging and ingredients
Strengthens focus on growth markets in biopharmaceutical, vaccine, nutraceutical and cosmetic segments
Aceto has consolidated and integrated its six manufacturing-related acquisitions over the past 18 months to achieve a hybrid manufacturing/distribution model providing key benefits to its customers in high-growth end markets including:
Pharmaceuticals and biopharmaceuticals
Vaccines
Nutraceuticals
Agriculture
Cosmetics
Specialty chemicals.
These developments are timely as the Covid-19 pandemic shows the fragility of global supply chains, requiring companies to focus on achieving supply chain resilience and security.
The company’s procurement teams, which are strategically located in centers of excellence in key regions across Asia, Europe and North America, represent a major resource for Aceto’s customers.
They are now strengthened by having access to Aceto’s own captive GMP manufacturing resources in addition to rigorously selected external suppliers.
Aceto’s operations in 10 countries handle more than 3,000 products, including reagents and process aids, intermediates, APIs and excipients.
Its capabilities span the entire R&D and product development/manufacturing spectrum, encompassing R&D, production, quality assurance, supply chain management, global sourcing, GMP grade manufacturing, and regulatory and quality compliance.
More info
